OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple ...

"The motherhood penalty -- the loss in lifetime earnings experienced by women raising children -- has become the most significant driver of the gender pay gap," the ...

Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this ...

Familial adenomatous polyposis is an inherited condition that significantly increases the risk for colon cancer. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 ...

Prostaglandins induce the regeneration of muscle in rodents and humans through the prostaglandin E2 receptor EP4 subtype receptor, but this therapeutic pathway's potential is limited due to systemic ...